Good Buffer-Based Cationic Lipids for Biodegradable mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for cationic lipids that can be synthesized efficiently and cheaply without forming toxic by-products, and that exhibit improved biodegradability and stability for effective in vivo delivery of nucleic acids, particularly mRNA, while maintaining a favorable safety profile.
Innovation Solution
The development of second-generation cationic lipids derived from 'Good' buffers, featuring ester moieties and short alkyl tails, which are synthesized from readily available starting reagents and include cleavable groups like esters and disulfides to enhance biodegradability and stability, forming lipid nanoparticles with improved generalized polarization (GP) values.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cationic lipids are synthesized for effective nucleic acid delivery, then delivery efficiency is improved, but toxic by-products may form and biodegradability may be reduced
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by incorporating specific ester moieties (butyl, isopropyl, pentan-3-yl) at defined positions in the lipid tail, changing the chemical parameters to achieve both effective delivery and improved biodegradability while reducing toxic by-product formation
Solution Approach 2:
The invention creates composite lipid structures combining ionizable head groups with specific ester-containing tail moieties, integrating multiple functional elements (cationic charge, ester bonds for degradation, hydrophobic tails) into a single molecular architecture that achieves multiple objectives simultaneously
2Object-affected harmful factors
If cationic lipids are designed for improved biodegradability with ester moieties, then safety profile is improved, but synthesis complexity may increase
Solution Approach 1:
The lipid molecule is segmented into distinct functional regions: an ionizable head group derived from Good's buffers and a tail region with specific ester moieties. This segmentation allows independent optimization of each region's properties and simplifies the synthesis pathway by using modular building blocks
Solution Approach 2:
The patent uses readily available Good's buffers as intermediary starting materials that already possess the desired ionizable head group structure. These intermediaries serve as pre-functionalized building blocks that reduce the number of synthesis steps required to achieve the final complex lipid structure
Data Source
AI summary
The present invention provides, in part, second generation “good” buffer-based cationic lipids of Formula (I), and subformulas thereof: Formula (I), (t), or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.